Genotoxicity in the absence of inflammation after tungsten inhalation in mice
Jorid B. Sørli (National Research Centre for the Working Environment, Copenhagen)
Alexander C.Ø. Jensen (National Research Centre for the Working Environment, Copenhagen)
Alicja Mortensen (National Research Centre for the Working Environment, Copenhagen)
Józef Szarek (University of Warmia and Mazury)
Claudia A.T. Gutierrez (National Research Centre for the Working Environment, Copenhagen, University of Copenhagen)
Iosif Hafez (The Cyprus Institute)
George Biskos (The Cyprus Institute, TU Delft - Atmospheric Remote Sensing)
Karin S. Hougaard (University of Copenhagen, National Research Centre for the Working Environment, Copenhagen)
Ulla Vogel (National Research Centre for the Working Environment, Copenhagen, Technical University of Denmark (DTU))
undefined More Authors
More Info
expand_more
Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.
Abstract
Tungsten is used in several applications and human exposure may occur. To assess its pulmonary toxicity, we exposed male mice to nose-only inhalation of tungsten particles at 9, 23 or 132 mg/m3 (Low, Mid and High exposure) (45 min/day, 5 days/week for 2 weeks). Increased genotoxicity (assessed by comet assay) was seen in bronchoalveolar (BAL) fluid cells at Low and High exposure. We measured acellular ROS production, and cannot exclude that ROS contributed to the observed genotoxicity. We saw no effects on body weight gain, pulmonary inflammation, lactate dehydrogenase or protein in BAL fluid, pathology of liver or kidney, or on sperm counts. In conclusion, tungsten showed non-dose dependent genotoxicity in the absence of inflammation and therefore interpreted to be primary genotoxicity. Based on genotoxicity, a Lowest Observed Adverse Effect Concentration (LOAEC) could be set at 9 mg/m3. It was not possible to establish a No Adverse Effect Concentration (NOAEC).